Navigation Links
Vical Announces News Release and Conference Call Schedule for 2007 Financial Results
Date:2/14/2008

SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the company will report financial results for the quarter and year ended December 31, 2007, before the opening of trading on Thursday, February 21, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, February 21. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast.

To listen to the conference call, dial in approximately ten minutes before the scheduled call to (888) 600-4883, or (913) 312-6683 for international participants, and reference confirmation code 5814630. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 5814630. The call also will be available live and archived through the events page at http://www.vical.com.

Invited analysts and institutional investors may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to info@vical.com or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vical to Present at BIO CEO and Investor Conference
2. Hollywood On the Hill - A Red Carpet Event on Capitol Hill Raises Awareness for Cervical Cancer Prevention and HPV-Related Technologies
3. National Cervical Cancer Coalition (NCCC) State Chapters to Provide Parents With Educational Forum to Discuss Cervical Cancer and HPV Vaccines
4. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
5. National Cervical Cancer Coalition Stresses Importance of Screening and Prevention During January Cervical Health Awareness Month
6. Study determines costs of breast and cervical cancer detection among low-income women
7. GlaxoSmithKline Receives FDA Complete Response Letter for Cervical Cancer Vaccine
8. Vical Expands Clinical Testing of DNA Vaccine Against H5N1 Pandemic Influenza
9. Post-treatment PET scans can reassure cervical cancer patients
10. PET Scans Can Spot Cervical Cancers Return
11. Pill Poses Little Cervical Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream ... procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a variety ... , dermaka cream is very effective for bruising and causes a rapid resolution ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Randall Markarian, DDS, are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s ... 15-16 at the Gateway Convention Center in Collinsville. , They expect ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in ... Sedona, surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The ... the Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, a global ... for clinical transfusion research programs and for the blood supply in the Netherlands, ... Predictive Analytical Rating Score (PREPAReS) study. , Currently in its sixth year, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: